Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Australian Clinical LabsASX:ACL +0.71%73 Gross Margin % is 22.13% as of Jun. 2026, which is 73% below its 10-year median of 82.18. GuruFocus rates ASX:ACL with a GF Score™ of 73/100 and a GF Value™ of A$2.95 (Fairly Valued). The stock has 8 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Australian Clinical Labs ranks better than 89.18% on this metric.
ASX:ACL's Gross Margin % is ranked better than 89.18% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.825
vs ASX:ACL: 83.18
Australian Clinical Labs had a gross margin of 22.13% for the quarter that ended in Jun. 2026 => Competition eroding margins
Australian Clinical Labs (ASX:ACL) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Australian Clinical Labs had a gross margin of 22.13% for the quarter that ended in Jun. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Australian Clinical Labs Gross Margin % Related Terms
Australian Clinical Labs Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ACL vs TMO, DHR, NTRA: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Australian Clinical Labs's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Australian Clinical Labs Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Australian Clinical Labs's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Australian Clinical Labs (ASX:ACL) has a Gross Margin % of 22.13% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Australian Clinical Labs and its competitors. This is 73% below median its historical median of 82.18. Over the past decade, Australian Clinical Labs' Gross Margin % has ranged from 79.02 to 83.18. According to the industry distribution chart, Australian Clinical Labs ranks #21 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 10.8%.
Is Australian Clinical Labs' Gross Margin % too high?
Australian Clinical Labs' current Gross Margin % of 22.13% is 73% below median its 10-year median of 82.18. Over the past 10 years, this metric has ranged from a low of 79.02 to a high of 83.18. The Medical Diagnostics & Research industry median Gross Margin % is 50.83. Australian Clinical Labs' value of 22.13% is 56.5% below this industry median. Based on the distribution chart, Australian Clinical Labs ranks #21 out of 194 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Australian Clinical Labs has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Australian Clinical Labs ranks #21 out of 194 companies for Gross Margin %. This places Australian Clinical Labs in the top 11% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 50.83. Australian Clinical Labs' value of 22.13% is 56.5% below this benchmark. Historically, Australian Clinical Labs' own Gross Margin % has ranged from 79.02 to 83.18 over the past decade. While the company's 10-year median is 82.18 vs. the industry median of 50.83, Australian Clinical Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.83, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Australian Clinical Labs's current Gross Margin % of 22.13% is 56.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Australian Clinical Labs and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australian Clinical Labs's current Gross Margin % is 22.13%, which is 73% below median its own 10-year median of 82.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Fairly Valued. The stock's GF Value™ is A$2.95, compared to a current price of A$2.84 — trading 3.7% below its estimated fair value. The current Gross Margin % is 22.13%, which is 73% below median its 10-year median of 82.18 and 56.5% below the Medical Diagnostics & Research industry median of 50.83. Australian Clinical Labs' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current Gross Margin % is 22.13% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?
Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued.
The current stock price of A$2.84 is trading 3.7% below its estimated GF Value™ of A$2.95.
GuruFocus considers Australian Clinical Labs to be Fairly Valued.
Key valuation signals for ASX:ACL:
Gross Margin %: 22.13% (73% below median its 10-year median of 82.18)
GF Value™: A$2.95 vs. price of A$2.84 (3.7% below fair value)
Industry Position: 56.5% below the Medical Diagnostics & Research median (#21 of 194)
No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
73GF Score
Get the complete analysis for ASX:ACL
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACL has been successfully added to your 
